Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus
Award Notice Posted
- Solicitation number
- W81K0225DA026
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Awarded
- to Qiagen, LLC
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- W81K0225DA026-W81K0225FA153 Federal contract award
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- Tacoma, Washington, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of the Army Medical Command has awarded a sole source Indefinite Delivery Indefinite Quantity contract to Qiagen, LLC for QuantiFERON TB Gold-Plus assay reagents used to detect Mycobacterium Tuberculosis immune responses through enzyme immunoassay testing at Madigan Army Medical Center in Tacoma, Washington. The five-year contract has a ceiling value of $485,895 and runs from October 1, 2025, through September 30, 2030. These specialized reagents are the only FDA-cleared interferon-gamma release assay compatible with the DiaSorin LIAISON XL analyzer at the facility, capable of processing at least 200 samples to support continuous laboratory operations for tuberculosis detection in military personnel and surrounding communities. The award was made under FAR 13.106-l(b)(l) as a non-competitive procurement due to the unique technical requirements and lack of alternative sources identified through market research.
Notice text
On 17 September 2025, Joint Base Lewis McChord Health Contracting Branch awarded sole source Indefinite Delivery Indefinite Quantity to Qiagen, LLC, 19300 Germantown Road Germantown, MD 20874-1415 for supplies: QuantiFERON TB Gold-Plus assay reagents for running QuantiFERON TB-Gold Plus for the detection of Mycobacterium Tuberculosis immune responses by enzyme immunoassay (EIA), for Madigan Army Medical Center, Tacoma WA 98431. This award was in accordance with FAR 13.106-l(b)(l). IAW FAR 5.301 this serves as the award notice under Solicitation W81K0225QA107 resulting in Contract Award W81K0225DA026. The North American Industry Classification Systems (NAICS) code for this work is 325413, with business size standard of 1,250 employees. The NAICS is for In-Vitro Diagnostic Substance Manufacturing. The Product Service Code (PSC) is 6550. The resulting contract has an order period of 01 October 2025- 30 September 2030 and the contract ceiling amount is $485,895.00. See attached J&A for further information.
Awarded contract W81K0225DA026 to QIAGEN, LLC for 485895.00 on 2025-09-17.
Files
| File | Type | Posted |
|---|---|---|
| JA Qiagen QFT FINAL 9-4-25 _Redacted.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Award Notice | |
| Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus | Solicitation | |
| Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus | Pre-Solicitation |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity